Cite
HARVARD Citation
ElNaggar, A. et al. (2016). Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer. Cancer biology & therapy. 17 (10), pp. 1107-1115. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
ElNaggar, A. et al. (2016). Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer. Cancer biology & therapy. 17 (10), pp. 1107-1115. [Online].